ESC 365 - Can we avoid randomized clinical trials for new CV drugs? .

ESC Premium Access

Can we avoid randomized clinical trials for new CV drugs? .

Session: Current controversies in clinical trial design

Topic: Cardiovascular Pharmacotherapy

Speaker: Ms K. Pieper (London, GB)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Ms Karen Pieper

Thrombosis Research Institute, London (United Kingdom of Great Britain & Northern Ireland)

2 presentations

0 follower

3 more presentations in this session

Critical issues in endpoint definition.

Speaker: Professor J. Tijssen (Amsterdam, NL)

Lost to follow-up in cardiovascular trials.

Speaker: Associate Professor V. Serebruany (Baltimore, US)

Current controversies in clinical trial design - Panel discussion.

Access the full session

Current controversies in clinical trial design

Speakers: Ms K. Pieper, Professor J. Tijssen, Associate Professor V. Serebruany

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources